Last reviewed · How we verify
Sitagliptin phosphate anhydrous formulation
Sitagliptin phosphate anhydrous formulation is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development.
At a glance
| Generic name | Sitagliptin phosphate anhydrous formulation |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sitagliptin phosphate anhydrous formulation CI brief — competitive landscape report
- Sitagliptin phosphate anhydrous formulation updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Sitagliptin phosphate anhydrous formulation
What is Sitagliptin phosphate anhydrous formulation?
Sitagliptin phosphate anhydrous formulation is a Small molecule drug developed by Merck Sharp & Dohme LLC.
Who makes Sitagliptin phosphate anhydrous formulation?
Sitagliptin phosphate anhydrous formulation is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
What development phase is Sitagliptin phosphate anhydrous formulation in?
Sitagliptin phosphate anhydrous formulation is in Phase 1.